DDInter1826 DDInter1679
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Sitagliptin
Tolazamide {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Sitagliptin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) DPP4
DPP4 {u} (Gene) is bound by {v} (Compound) Sitagliptin
Tolazamide {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sitagliptin
Tolazamide {u} (Compound) causes {v} (Side Effect) Vertigo
Vertigo {u} (Side Effect) is caused by {v} (Compound) Quetiapine
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Sitagliptin
Tolazamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Tolazamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sitagliptin
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Tolazamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with DPP4 (Gene) and DPP4 (Gene) is bound by Sitagliptin (Compound)
Tolazamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Tolazamide (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Tolazamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Tolazamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)